Goldman Sachs
MYGN icon

Goldman Sachs’s Myriad Genetics MYGN Stock Holding History

Goldman Sachs’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-200
Closed -$6K – 5870
2018
Q1 		$6K Sell
200
-3,800
-95% -$129K ﹤0.01% 5789
2017
Q4 		$137K Sell
4,000
-7,100
-64% -$240K ﹤0.01% 5606
2017
Q3 		$402K Sell
11,100
-10,600
-49% -$302K ﹤0.01% 5261
2017
Q2 		$561K Buy
21,700
+8,800
+68% +$187K ﹤0.01% 4991
2017
Q1 		$248K Sell
12,900
-8,900
-41% -$158K ﹤0.01% 5584
2016
Q4 		$363K Buy
21,800
+4,700
+27% +$85K ﹤0.01% 5332
2016
Q3 		$352K Buy
17,100
+9,400
+122% +$238K ﹤0.01% 5356
2016
Q2 		$236K Sell
7,700
-38,000
-83% -$1.32M ﹤0.01% 5560
2016
Q1 		$1.71M Buy
45,700
+1,000
+2% +$37.7K ﹤0.01% 3625
2015
Q4 		$1.93M Sell
44,700
-3,900
-8% -$165K ﹤0.01% 3663
2015
Q3 		$1.82M Sell
48,600
-100
-0.2% -$3.55K ﹤0.01% 3896
2015
Q2 		$1.66M Sell
48,700
-34,400
-41% -$1.17M ﹤0.01% 4032
2015
Q1 		$2.94M Sell
83,100
-6,400
-7% -$229K ﹤0.01% 3409
2014
Q4 		$3.05M Sell
89,500
-41,200
-32% -$1.46M ﹤0.01% 3441
2014
Q3 		$5.04M Buy
130,700
+53,800
+70% +$2.01M ﹤0.01% 3005
2014
Q2 		$2.99M Sell
76,900
-17,600
-19% -$655K ﹤0.01% 3588
2014
Q1 		$3.23M Buy
94,500
+51,000
+117% +$1.58M ﹤0.01% 3518
2013
Q4 		$913K Sell
43,500
-3,700
-8% -$93.6K ﹤0.01% 4817
2013
Q3 		$1.11M Buy
47,200
+25,200
+115% +$716K ﹤0.01% 4510
2013
Q2 		$591K Buy
+22,000
New +$638K ﹤0.01% 4800

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's MYGN Position: Q1 2026 in Review

Goldman Sachs increased its Myriad Genetics (MYGN) stake by 9.5% in Q1 2026, buying an estimated $1.07M and bringing the position to 2,366,092 shares worth $10.6M. The position accounts for ﹤0.01% of the portfolio, ranked #3020.

Goldman Sachs first reported a position in MYGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $68.8M in Q3 2021. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Goldman Sachs held 2,366,092 shares of Myriad Genetics worth $10.6M as of Q1 2026.
  • Goldman Sachs bought 205,810 Myriad Genetics shares in Q1 2026, an estimated $1.07M.
  • Myriad Genetics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3020 holding.
  • Goldman Sachs first reported a position in Myriad Genetics in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's Myriad Genetics position peaked at $68.8M in Q3 2021.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.